In Reply We appreciate the comments by Hutton et al regarding dosing frequency and the need to examine alternative dosing intervals. Given our study design, which used a single infusion, we do not know whether a different dosing interval would have been more or less effective or generated more or fewer adverse events in this cohort. However, because a single infusion of zoledronic acid has been shown to exert a positive effect on skeletal health for up to 5 years,1,2 we chose a 2-year dosing interval. We agree that additional research needs to be done on the dosing frequency, especially focusing on frail elderly patients for whom there are limited data on osteoporosis treatment.
Greenspan SL, Perera S, Resnick NM. Dosing Strategies of Bone-Targeting Agents—Reply. JAMA Intern Med. 2015;175(11):1865-1866. doi:10.1001/jamainternmed.2015.4799